Gianfranco Nazzi – CEO, Almirall
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Almirall, S.A. is a Spanish pharmaceutical company, with headquarters in Barcelona, founded in 1943.[4]
In 2016, it generated a total revenue of 859.3 million € [5] and became the leading pharmaceutical company in R&D investment in Spain.
With over 1,975 employees (2016), it has a presence, through its 13 affiliates in Europe and the United States.
Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (CSIC), the Instituto de Investigación Biomédica and the Parc Científic de Barcelona in Spain. Highlighted among the international alliances are those with the Imperial College of London (United Kingdom) and the National Institute of Health (NIH) in the United States. Almirall participated in the creation of the Barcelona Respiratory Network Foundation. In Europe, the company has contributed in several projects with the Innovative Medicines Initiative (IMI).
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Rui Ferreira Dos Santos, country manager for Spanish pharmaceutical company, Almirall provides readers with an update on the company’s new medicines and how their global strategy to become dermatology specialists…
Bertil Lindmark, Almirall’s chief scientific officer, discusses the state of R&D in Spain today and outlines the key strategies the company is taking to provide valuable medicines and cutting-edge technologies…
Eduardo Sanchiz took over as CEO of Spain’s flagship pharmaceutical company Almirall in 2011, after Jorge Gallardo stepped down in this role while staying as Chairman of the Board. Many…
Israel Garcia, general manager of Spain for Almirall, discusses market access issues in the company’s home country and highlights the affiliate’s commitment to internal R&D. What was the reason for…
Almirall Portugal stopped all commercial activity in 2011 to focus only on the market access of new, innovative products being introduced through the organization’s active R&D pipeline. Country Manager Rui…
Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well…
Almirall was opened through the acquisition of Hermal in 2007. What impact did that have on Almirall’s operations in central Europe, and where does Austria fit in Almirall’s picture today?…
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
Ana Fernández of Théa Spain discusses the strategic importance of the Spanish affiliate – the group’s oldest, current trends in Spanish ophthalmology, and what differentiates Théa – as a family-run…
Spanish stakeholders have been trailblazing the concept of the “liquid hospital”, which envisions the virtual and physical expansion of healthcare provision beyond the parameters of the traditional centralized hospital structure.…
From Big Data to healthcare algorithms to the healthcare continuum. Philips’ intention to be recognized by citizens as the company that helps people lead healthier lives covers all aspects of…
Margarita Alfonsel, general secretary of Fenin, Spain’s medtech association, outlines the sector’s success stories from the past four years and her ongoing priorities. What is the role of Fenin as…
Miguel Angel Calleja, president of the Spanish Society of Hospital Pharmacists (SEFH) introduces the society and the important role it plays in Spain’s healthcare system as the perfect partner for…
Dr Carlos Macaya received worldwide recognition as a cardiovascular surgeon after he operated on the tender heart of Mother Teresa. Now, as the President of the Spanish Heart Foundation, he…
Reig Jofre’s Ignasi Biosca outlines recent changes at the Spanish family-owned company, preserving its original ethos, portfolio development and internationalization plans. Can you update us on some of the recent…
Dr. Carlos Macaya, one of the world’s most renowned cardiologists and president of the Spanish Heart Foundation (FEC), outlines the landscape for cardiovascular disease in Spain. Could you please start…
With Spain now on the road to economic recovery following the ravages of the global financial crisis, multinational pharmaceutical companies are seeing the country as a top investment destination once…
Josep Taberno MD PhD, director of VHIO, introduces the important work being conducted by the cancer institute in Spain as well as emerging trends in oncology. Can you tell us…
Ricardo Martinez Murillo, director of the Cajal Institute – a neuroscience research center assigned to the Spanish Research Council (CSIC) and the oldest neurobiology research center in Spain – discusses…
Consuelo Martín de Dios, managing director of the Roche Institute Foundation discusses the legacy and movements of the organization as well as the challenges, opportunities, and future of Personalized Precision…
See our Cookie Privacy Policy Here
